Document |
Document Title |
WO/2024/088189A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
|
WO/2024/091894A1 |
The present disclosure is directed to novel PNU Anthracycline Derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the above disclosure. The disclosure is also directed to pharmac...
|
WO/2024/088307A1 |
Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
WO/2024/090469A1 |
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
WO/2024/082645A1 |
The present application relates to the technical field of organic electroluminescence, and relates to an organic compound, an organic electroluminescent device using same, and an electronic device. The organic compound has a structure as...
|
WO/2024/083980A1 |
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
WO/2024/086296A1 |
The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
|
WO/2024/084390A1 |
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or periphe...
|
WO/2024/085661A1 |
Provided are triheterocyclic compounds, and more specifically triheterocyclic compounds useful as KRAS protein inhibitors, and a pharmaceutical composition including the same for treating cancers.
|
WO/2024/086634A1 |
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...
|
WO/2024/083223A1 |
The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...
|
WO/2024/085036A1 |
A compound represented by formula (1) (the symbols in formula (1) are as defined in the description); an organic electroluminescent element containing the compound; and an electronic appliance containing the organic electroluminescent el...
|
WO/2024/083146A1 |
The present invention relates to a compound of general formula (A) and a pharmaceutical composition thereof. The compound of formula (A) provided in the present invention can be used for preventing and/or treating diseases related to the...
|
WO/2024/083168A1 |
Provided herein are oxazepinyl compounds comprising a 6-aza moiety that are useful in the treatment of cancers.
|
WO/2024/083933A1 |
There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), (I) and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulator...
|
WO/2024/078263A1 |
The present invention relates to a macrocyclic heterocyclic compound as a selective inhibitor of a clinical mutant of EGFR kinase, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt ther...
|
WO/2024/078372A1 |
Provided are a heterocyclic substituted phenol derivative, a preparation method therefor, and a use thereof. Specifically, provided are compounds of formulas (I-1), (II-1B), (III), and (IV), stereoisomers thereof, pharmaceutically accept...
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
WO/2024/081927A1 |
Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
|
WO/2024/078620A1 |
A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...
|
WO/2024/074080A1 |
Disclosed in the present invention are a highly effective antiviral derivative and a use thereof. The derivative is a compound shown in formula (I-0) or a hydrate, solvate, optical isomer, polymorphic substance, isotope derivative, or ph...
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
WO/2024/075815A1 |
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
WO/2024/076693A1 |
Disclosed herein are compounds of Formula I and methods for using the same for treating or preventing an infection caused by a mycobacterium in a subject in need thereof. The method comprises administering to the subject the compound of ...
|
WO/2024/067465A1 |
Provided are a compound useful as a KIF18A inhibitor, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, a pharmaceutical composition and a preparation comprising the compound or the pharmaceutically acceptable salt,...
|
WO/2024/068159A1 |
This application relates generally to the field of synthesis, formulations and perivascular treatment methods involving cyclic ester derivatives of everolimus.
|
WO/2024/073507A1 |
Described herein are macrocyclic compounds of Formulas (Al), (BI), and (CI) which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a com...
|
WO/2024/073587A1 |
Compounds and methods for inhibiting Nrf2 by activating KEAP1.
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
WO/2024/067575A1 |
Disclosed are a nitrogen-containing polycyclic compound, and a pharmaceutical composition and use thereof. The nitrogen-containing polycyclic compound of the present invention is a nitrogen-containing polycyclic compound represented by f...
|
WO/2024/068926A1 |
The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, ...
|
WO/2024/073576A1 |
Provided herein are compounds of Formula (I) which are inhibitors of furin, pharmaceutical compositions containing them, processes for their preparation, and their use in therapy (e.g., for the treatment of respiratory syncytial virus).
|
WO/2024/061370A1 |
Disclosed in the present invention is a pyrimidine-fused ring compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof. In addition, further disclosed in the prese...
|
WO/2024/061853A1 |
The invention provides compounds having the general formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein A, L, n, and R1 to R3 are as defined herein, compositions including the compounds, processes of manufacturing t...
|
WO/2024/063648A1 |
The present invention is directed to a scaffold and a compound for targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs). The scaffold comprises a (4-quinoinolyl)glycinyl-2-cyanopyrrolidine scaffold that i...
|
WO/2024/063578A1 |
The present invention relates to a novel tetraheterocycle compound and, more specifically, to a novel tetraheterocycle compound useful as a KRAS protein inhibitor, an isomer, and a pharmaceutical composition for cancer treatment comprisi...
|
WO/2024/061371A1 |
Provided is a small-molecule steroid synthetase inhibitor. Further provided is use of the steroid synthetase inhibitors.
|
WO/2024/061257A1 |
Disclosed are a polycyclic N-heterocyclic ketone compound and use thereof, and specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
WO/2024/056775A1 |
The present invention is directed to compounds of formula IIa. These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the inventi...
|
WO/2024/056779A1 |
The invention relates to crystalline form of (3S,7S,10R,13R)-13-benzyl-20-fluoro-7-isobutyl-N-(2-(3-metho
xy-1,2,4- oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2
,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14- tetrade...
|
WO/2024/055196A1 |
The present invention relates to an acceptor-donor-acceptor (A-D-A) type organic compound and a preparation method therefor. The material has a thermal activation delayed fluorescence property; a monomolecular structure presents a face-t...
|
WO/2024/059249A1 |
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
|
WO/2023/159307A9 |
Disclosed are compounds and pharmaceutically acceptable salts of formula (I), which feature either a N-(1H-pyrazol-3-yl)pyridin-2-amine or a N-(1H-pyrazol-3-yl)pyrimidin-4-amine core structure. These compounds may be used in the treatmen...
|
WO/2024/056798A1 |
The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically 5 acceptable salts thereof, and to their use as pha...
|
WO/2024/057020A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
WO/2024/055195A1 |
The present invention relates to a high-efficiency organic electroluminescent device and a preparation method therefor. A hole injection layer, a hole transport layer, an electron blocking layer, a light-emitting layer, a hole blocking l...
|
WO/2024/059558A1 |
The present disclosure relates generally to compounds of Formulae (l-A), (l-B1), (l-C) and ((l-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, method...
|